Citizens reiterates USD 42.00 target for IDEAYA Biosciences stock

Published on 10/20/2026 at 20:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEAYA's London R&D Day is set for November 16, 2026. IDEAYA Biosciences stock costs EUR 31.61 on October 20, 2026 at 8:09 p.m. CEST.

Analyst view and reporting date

Citizens reiterated a USD 42.00 target on October 19, 2026.
Second-quarter 2026 revenue was USD 8.86 million and diluted earnings per share were minus USD 1.22.
IDEAYA Biosciences stock costs EUR 31.61 at Lang & Schwarz on October 20, 2026 at 8:09 p.m. CEST.
The next estimated earnings date is November 9, 2026.

IDYA, US45166A1025, Illustration mit AI erstellt.

IDEAYA Biosciences (ISIN US45166A1025) received a reiterated USD 42.00 price target and Market Outperform rating from Citizens on October 19, 2026, ahead of the company's ESMO presentations, according to Investing.com. The target is 18.31 percent above the USD 35.50 Nasdaq price on October 20, 2026 at 2:13 p.m. EDT. IDEAYA Biosciences was trading at EUR 31.61 at Lang & Schwarz on October 20, 2026 at 8:09 p.m. CEST.

Quarterly figures set the baseline

IDEAYA reported USD 8.86 million of revenue for the second quarter of 2026, compared with USD 6.56 million in the first quarter. Net loss widened from USD 98.54 million to USD 112.45 million over the same periods, while diluted earnings per share moved from minus USD 1.11 to minus USD 1.22, according to Yahoo Finance.

Stock position remains wide

Yahoo Finance listed a 52-week Nasdaq range of USD 26.81 to USD 42.68 on October 16, 2026. The same page showed a USD 3.17 billion market capitalization and a 4.98 percent year-to-date gain. These figures place the company between a recent low and its yearly high while the euro quotation provides the German trading perspective.

What dates matter next?

The next estimated earnings date is November 9, 2026, according to Yahoo Finance. IDEAYA's investor-relations page lists a London R&D Day for November 16, 2026, with a two-hour program beginning at 12:00 p.m. EST, according to IDEAYA Biosciences.

The analyst target puts the main valuation question in dollars rather than euros. Citizens' USD 42.00 objective stands 18.31 percent above the USD 35.50 Nasdaq price used for the calculation, while the company remains loss-making in the second quarter. The upcoming earnings date and R&D Day give investors two dated checkpoints for the pipeline story.

Price and investor perspective

IDEAYA combines a USD 3.17 billion market capitalization with a second-quarter 2026 net loss of USD 112.45 million. Its precision oncology pipeline includes darovasertib, IDE849 and other targeted programs, while the reported revenue base remains small relative to development spending.

The further course of trading is shown by the continuously updated real-time quote of IDEAYA Biosciences stock.